Newton Biocapital — 2019 Investments

1 investments dated 2019 · listed companies and verified rows first · show all

Acticor Biotechacticor-biotech.com in 𝕏Nov 2019

Acticor Biotech develops Glenzocimab, a therapeutic candidate targeting GPVI for treating acute ischemic stroke and STEMI.

BiotechDigital HealthMedical Devices

Gilles AVENARD(Chief Executive Officer)

Co-investorsAgoranov CapDecisif Management Karista Anaxago GO Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.